1 Report Business Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Drugs for Oncology Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
        1.2.2 Chemotherapy
        1.2.3 Targeted Therapy
        1.2.4 Immunotherapy (Biologic Therapy)
        1.2.5 Hormonal Therapy
        1.2.6 Others
    1.3 Market by Application
        1.3.1 Global Drugs for Oncology Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
        1.3.2 Blood Cancer
        1.3.3 Breast Cancer
        1.3.4 Gastrointestinal Cancer
        1.3.5 Prostate Cancer
        1.3.6 Respiratory/Lung Cancer
        1.3.7 Others
    1.4 Study Objectives
    1.5 Years Considered
2 Global Growth Trends
    2.1 Global Drugs for Oncology Market Perspective (2017-2028)
    2.2 Drugs for Oncology Growth Trends by Region
        2.2.1 Drugs for Oncology Market Size by Region: 2017 VS 2021 VS 2028
        2.2.2 Drugs for Oncology Historic Market Size by Region (2017-2022)
        2.2.3 Drugs for Oncology Forecasted Market Size by Region (2023-2028)
    2.3 Drugs for Oncology Market Dynamics
        2.3.1 Drugs for Oncology Industry Trends
        2.3.2 Drugs for Oncology Market Drivers
        2.3.3 Drugs for Oncology Market Challenges
        2.3.4 Drugs for Oncology Market Restraints
3 Competition Landscape by Key Players
    3.1 Global Top Drugs for Oncology Players by Revenue
        3.1.1 Global Top Drugs for Oncology Players by Revenue (2017-2022)
        3.1.2 Global Drugs for Oncology Revenue Market Share by Players (2017-2022)
    3.2 Global Drugs for Oncology Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Players Covered: Ranking by Drugs for Oncology Revenue
    3.4 Global Drugs for Oncology Market Concentration Ratio
        3.4.1 Global Drugs for Oncology Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Drugs for Oncology Revenue in 2021
    3.5 Drugs for Oncology Key Players Head office and Area Served
    3.6 Key Players Drugs for Oncology Product Solution and Service
    3.7 Date of Enter into Drugs for Oncology Market
    3.8 Mergers & Acquisitions, Expansion Plans
4 Drugs for Oncology Breakdown Data by Type
    4.1 Global Drugs for Oncology Historic Market Size by Type (2017-2022)
    4.2 Global Drugs for Oncology Forecasted Market Size by Type (2023-2028)
5 Drugs for Oncology Breakdown Data by Application
    5.1 Global Drugs for Oncology Historic Market Size by Application (2017-2022)
    5.2 Global Drugs for Oncology Forecasted Market Size by Application (2023-2028)
6 North America
    6.1 North America Drugs for Oncology Market Size (2017-2028)
    6.2 North America Drugs for Oncology Market Size by Type
        6.2.1 North America Drugs for Oncology Market Size by Type (2017-2022)
        6.2.2 North America Drugs for Oncology Market Size by Type (2023-2028)
        6.2.3 North America Drugs for Oncology Market Share by Type (2017-2028)
    6.3 North America Drugs for Oncology Market Size by Application
        6.3.1 North America Drugs for Oncology Market Size by Application (2017-2022)
        6.3.2 North America Drugs for Oncology Market Size by Application (2023-2028)
        6.3.3 North America Drugs for Oncology Market Share by Application (2017-2028)
    6.4 North America Drugs for Oncology Market Size by Country
        6.4.1 North America Drugs for Oncology Market Size by Country (2017-2022)
        6.4.2 North America Drugs for Oncology Market Size by Country (2023-2028)
        6.4.3 U.S.
        6.4.4 Canada
7 Europe
    7.1 Europe Drugs for Oncology Market Size (2017-2028)
    7.2 Europe Drugs for Oncology Market Size by Type
        7.2.1 Europe Drugs for Oncology Market Size by Type (2017-2022)
        7.2.2 Europe Drugs for Oncology Market Size by Type (2023-2028)
        7.2.3 Europe Drugs for Oncology Market Share by Type (2017-2028)
    7.3 Europe Drugs for Oncology Market Size by Application
        7.3.1 Europe Drugs for Oncology Market Size by Application (2017-2022)
        7.3.2 Europe Drugs for Oncology Market Size by Application (2023-2028)
        7.3.3 Europe Drugs for Oncology Market Share by Application (2017-2028)
    7.4 Europe Drugs for Oncology Market Size by Country
        7.4.1 Europe Drugs for Oncology Market Size by Country (2017-2022)
        7.4.2 Europe Drugs for Oncology Market Size by Country (2023-2028)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic Countries
8 Asia-Pacific
    8.1 Asia-Pacific Drugs for Oncology Market Size (2017-2028)
    8.2 Asia-Pacific Drugs for Oncology Market Size by Type
        8.2.1 Asia-Pacific Drugs for Oncology Market Size by Type (2017-2022)
        8.2.2 Asia-Pacific Drugs for Oncology Market Size by Type (2023-2028)
        8.2.3 Asia-Pacific Drugs for Oncology Market Share by Type (2017-2028)
    8.3 Asia-Pacific Drugs for Oncology Market Size by Application
        8.3.1 Asia-Pacific Drugs for Oncology Market Size by Application (2017-2022)
        8.3.2 Asia-Pacific Drugs for Oncology Market Size by Application (2023-2028)
        8.3.3 Asia-Pacific Drugs for Oncology Market Share by Application (2017-2028)
    8.4 Asia-Pacific Drugs for Oncology Market Size by Region
        8.4.1 Asia-Pacific Drugs for Oncology Market Size by Region (2017-2022)
        8.4.2 Asia-Pacific Drugs for Oncology Market Size by Region (2023-2028)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia 
9 Latin America
    9.1 Latin America Drugs for Oncology Market Size (2017-2028)
    9.2 Latin America Drugs for Oncology Market Size by Type
        9.2.1 Latin America Drugs for Oncology Market Size by Type (2017-2022)
        9.2.2 Latin America Drugs for Oncology Market Size by Type (2023-2028)
        9.2.3 Latin America Drugs for Oncology Market Share by Type (2017-2028)
    9.3 Latin America Drugs for Oncology Market Size by Application
        9.3.1 Latin America Drugs for Oncology Market Size by Application (2017-2022)
        9.3.2 Latin America Drugs for Oncology Market Size by Application (2023-2028)
        9.3.3 Latin America Drugs for Oncology Market Share by Application (2017-2028)
    9.4 Latin America Drugs for Oncology Market Size by Country
        9.4.1 Latin America Drugs for Oncology Market Size by Country (2017-2022)
        9.4.2 Latin America Drugs for Oncology Market Size by Country (2023-2028)
        9.4.3 Mexico
        9.4.4 Brazil
10 Middle East & Africa
    10.1 Middle East & Africa Drugs for Oncology Market Size (2017-2028)
    10.2 Middle East & Africa Drugs for Oncology Market Size by Type
        10.2.1 Middle East & Africa Drugs for Oncology Market Size by Type (2017-2022)
        10.2.2 Middle East & Africa Drugs for Oncology Market Size by Type (2023-2028)
        10.2.3 Middle East & Africa Drugs for Oncology Market Share by Type (2017-2028)
    10.3 Middle East & Africa Drugs for Oncology Market Size by Application
        10.3.1 Middle East & Africa Drugs for Oncology Market Size by Application (2017-2022)
        10.3.2 Middle East & Africa Drugs for Oncology Market Size by Application (2023-2028)
        10.3.3 Middle East & Africa Drugs for Oncology Market Share by Application (2017-2028)
    10.4 Middle East & Africa Drugs for Oncology Market Size by Country
        10.4.1 Middle East & Africa Drugs for Oncology Market Size by Country (2017-2022)
        10.4.2 Middle East & Africa Drugs for Oncology Market Size by Country (2023-2028)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE
11 Key Players Profiles
    11.1 Roche
        11.1.1 Roche Company Details
        11.1.2 Roche Business Overview
        11.1.3 Roche Drugs for Oncology Introduction
        11.1.4 Roche Revenue in Drugs for Oncology Business (2017-2022)
        11.1.5 Roche Recent Developments
    11.2 Celgene
        11.2.1 Celgene Company Details
        11.2.2 Celgene Business Overview
        11.2.3 Celgene Drugs for Oncology Introduction
        11.2.4 Celgene Revenue in Drugs for Oncology Business (2017-2022)
        11.2.5 Celgene Recent Developments
    11.3 Novartis
        11.3.1 Novartis Company Details
        11.3.2 Novartis Business Overview
        11.3.3 Novartis Drugs for Oncology Introduction
        11.3.4 Novartis Revenue in Drugs for Oncology Business (2017-2022)
        11.3.5 Novartis Recent Developments
    11.4 Bristol-Myers Squibb
        11.4.1 Bristol-Myers Squibb Company Details
        11.4.2 Bristol-Myers Squibb Business Overview
        11.4.3 Bristol-Myers Squibb Drugs for Oncology Introduction
        11.4.4 Bristol-Myers Squibb Revenue in Drugs for Oncology Business (2017-2022)
        11.4.5 Bristol-Myers Squibb Recent Developments
    11.5 Johnson & Johnson
        11.5.1 Johnson & Johnson Company Details
        11.5.2 Johnson & Johnson Business Overview
        11.5.3 Johnson & Johnson Drugs for Oncology Introduction
        11.5.4 Johnson & Johnson Revenue in Drugs for Oncology Business (2017-2022)
        11.5.5 Johnson & Johnson Recent Developments
    11.6 Merck & Co.
        11.6.1 Merck & Co. Company Details
        11.6.2 Merck & Co. Business Overview
        11.6.3 Merck & Co. Drugs for Oncology Introduction
        11.6.4 Merck & Co. Revenue in Drugs for Oncology Business (2017-2022)
        11.6.5 Merck & Co. Recent Developments
    11.7 AstraZeneca
        11.7.1 AstraZeneca Company Details
        11.7.2 AstraZeneca Business Overview
        11.7.3 AstraZeneca Drugs for Oncology Introduction
        11.7.4 AstraZeneca Revenue in Drugs for Oncology Business (2017-2022)
        11.7.5 AstraZeneca Recent Developments
    11.8 Pfizer
        11.8.1 Pfizer Company Details
        11.8.2 Pfizer Business Overview
        11.8.3 Pfizer Drugs for Oncology Introduction
        11.8.4 Pfizer Revenue in Drugs for Oncology Business (2017-2022)
        11.8.5 Pfizer Recent Developments
    11.9 Amgen
        11.9.1 Amgen Company Details
        11.9.2 Amgen Business Overview
        11.9.3 Amgen Drugs for Oncology Introduction
        11.9.4 Amgen Revenue in Drugs for Oncology Business (2017-2022)
        11.9.5 Amgen Recent Developments
    11.10 Eli Lilly
        11.10.1 Eli Lilly Company Details
        11.10.2 Eli Lilly Business Overview
        11.10.3 Eli Lilly Drugs for Oncology Introduction
        11.10.4 Eli Lilly Revenue in Drugs for Oncology Business (2017-2022)
        11.10.5 Eli Lilly Recent Developments
    11.11 AbbVie
        11.11.1 AbbVie Company Details
        11.11.2 AbbVie Business Overview
        11.11.3 AbbVie Drugs for Oncology Introduction
        11.11.4 AbbVie Revenue in Drugs for Oncology Business (2017-2022)
        11.11.5 AbbVie Recent Developments
    11.12 Takeda
        11.12.1 Takeda Company Details
        11.12.2 Takeda Business Overview
        11.12.3 Takeda Drugs for Oncology Introduction
        11.12.4 Takeda Revenue in Drugs for Oncology Business (2017-2022)
        11.12.5 Takeda Recent Developments
    11.13 Astellas
        11.13.1 Astellas Company Details
        11.13.2 Astellas Business Overview
        11.13.3 Astellas Drugs for Oncology Introduction
        11.13.4 Astellas Revenue in Drugs for Oncology Business (2017-2022)
        11.13.5 Astellas Recent Developments
    11.14 Ipsen
        11.14.1 Ipsen Company Details
        11.14.2 Ipsen Business Overview
        11.14.3 Ipsen Drugs for Oncology Introduction
        11.14.4 Ipsen Revenue in Drugs for Oncology Business (2017-2022)
        11.14.5 Ipsen Recent Developments
    11.15 Sanofi
        11.15.1 Sanofi Company Details
        11.15.2 Sanofi Business Overview
        11.15.3 Sanofi Drugs for Oncology Introduction
        11.15.4 Sanofi Revenue in Drugs for Oncology Business (2017-2022)
        11.15.5 Sanofi Recent Developments
    11.16 Bayer
        11.16.1 Bayer Company Details
        11.16.2 Bayer Business Overview
        11.16.3 Bayer Drugs for Oncology Introduction
        11.16.4 Bayer Revenue in Drugs for Oncology Business (2017-2022)
        11.16.5 Bayer Recent Developments
    11.17 Biogen Idec
        11.17.1 Biogen Idec Company Details
        11.17.2 Biogen Idec Business Overview
        11.17.3 Biogen Idec Drugs for Oncology Introduction
        11.17.4 Biogen Idec Revenue in Drugs for Oncology Business (2017-2022)
        11.17.5 Biogen Idec Recent Developments
    11.18 Teva
        11.18.1 Teva Company Details
        11.18.2 Teva Business Overview
        11.18.3 Teva Drugs for Oncology Introduction
        11.18.4 Teva Revenue in Drugs for Oncology Business (2017-2022)
        11.18.5 Teva Recent Developments
    11.19 Otsuka
        11.19.1 Otsuka Company Details
        11.19.2 Otsuka Business Overview
        11.19.3 Otsuka Drugs for Oncology Introduction
        11.19.4 Otsuka Revenue in Drugs for Oncology Business (2017-2022)
        11.19.5 Otsuka Recent Developments
    11.20 Eisai
        11.20.1 Eisai Company Details
        11.20.2 Eisai Business Overview
        11.20.3 Eisai Drugs for Oncology Introduction
        11.20.4 Eisai Revenue in Drugs for Oncology Business (2017-2022)
        11.20.5 Eisai Recent Developments
    11.21 Merck KGaA
        11.21.1 Merck KGaA Company Details
        11.21.2 Merck KGaA Business Overview
        11.21.3 Merck KGaA Drugs for Oncology Introduction
        11.21.4 Merck KGaA Revenue in Drugs for Oncology Business (2017-2022)
        11.21.5 Merck KGaA Recent Developments
    11.22 Gilead Sciences
        11.22.1 Gilead Sciences Company Details
        11.22.2 Gilead Sciences Business Overview
        11.22.3 Gilead Sciences Drugs for Oncology Introduction
        11.22.4 Gilead Sciences Revenue in Drugs for Oncology Business (2017-2022)
        11.22.5 Gilead Sciences Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Author Details
    13.3 Disclaimer
                  
              

                

                 
List of Tables
    Table 1. Global Drugs for Oncology Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
    Table 2. Key Players of Chemotherapy
    Table 3. Key Players of Targeted Therapy
    Table 4. Key Players of Immunotherapy (Biologic Therapy)
    Table 5. Key Players of Hormonal Therapy
    Table 6. Key Players of Others
    Table 7. Global Drugs for Oncology Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
    Table 8. Global Drugs for Oncology Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
    Table 9. Global Drugs for Oncology Market Size by Region (2017-2022) & (US$ Million)
    Table 10. Global Drugs for Oncology Market Share by Region (2017-2022)
    Table 11. Global Drugs for Oncology Forecasted Market Size by Region (2023-2028) & (US$ Million)
    Table 12. Global Drugs for Oncology Market Share by Region (2023-2028)
    Table 13. Drugs for Oncology Market Trends
    Table 14. Drugs for Oncology Market Drivers
    Table 15. Drugs for Oncology Market Challenges
    Table 16. Drugs for Oncology Market Restraints
    Table 17. Global Drugs for Oncology Revenue by Players (2017-2022) & (US$ Million)
    Table 18. Global Drugs for Oncology Revenue Share by Players (2017-2022)
    Table 19. Global Top Drugs for Oncology by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Oncology as of 2021)
    Table 20. Ranking of Global Top Drugs for Oncology Companies by Revenue (US$ Million) in 2021
    Table 21. Global 5 Largest Players Market Share by Drugs for Oncology Revenue (CR5 and HHI) & (2017-2022)
    Table 22. Key Players Headquarters and Area Served
    Table 23. Key Players Drugs for Oncology Product Solution and Service
    Table 24. Date of Enter into Drugs for Oncology Market
    Table 25. Mergers & Acquisitions, Expansion Plans
    Table 26. Global Drugs for Oncology Market Size by Type (2017-2022) & (US$ Million)
    Table 27. Global Drugs for Oncology Revenue Market Share by Type (2017-2022)
    Table 28. Global Drugs for Oncology Forecasted Market Size by Type (2023-2028) & (US$ Million)
    Table 29. Global Drugs for Oncology Revenue Market Share by Type (2023-2028)
    Table 30. Global Drugs for Oncology Market Size by Application (2017-2022) & (US$ Million)
    Table 31. Global Drugs for Oncology Revenue Share by Application (2017-2022)
    Table 32. Global Drugs for Oncology Forecasted Market Size by Application (2023-2028) & (US$ Million)
    Table 33. Global Drugs for Oncology Revenue Share by Application (2023-2028)
    Table 34. North America Drugs for Oncology Market Size by Type (2017-2022) & (US$ Million)
    Table 35. North America Drugs for Oncology Market Size by Type (2023-2028) & (US$ Million)
    Table 36. North America Drugs for Oncology Market Size by Application (2017-2022) & (US$ Million)
    Table 37. North America Drugs for Oncology Market Size by Application (2023-2028) & (US$ Million)
    Table 38. North America Drugs for Oncology Market Size by Country (2017-2022) & (US$ Million)
    Table 39. North America Drugs for Oncology Market Size by Country (2023-2028) & (US$ Million)
    Table 40. Europe Drugs for Oncology Market Size by Type (2017-2022) & (US$ Million)
    Table 41. Europe Drugs for Oncology Market Size by Type (2023-2028) & (US$ Million)
    Table 42. Europe Drugs for Oncology Market Size by Application (2017-2022) & (US$ Million)
    Table 43. Europe Drugs for Oncology Market Size by Application (2023-2028) & (US$ Million)
    Table 44. Europe Drugs for Oncology Market Size by Country (2017-2022) & (US$ Million)
    Table 45. Europe Drugs for Oncology Market Size by Country (2023-2028) & (US$ Million)
    Table 46. Asia Pacific Drugs for Oncology Market Size by Type (2017-2022) & (US$ Million)
    Table 47. Asia Pacific Drugs for Oncology Market Size by Type (2023-2028) & (US$ Million)
    Table 48. Asia Pacific Drugs for Oncology Market Size by Application (2017-2022) & (US$ Million)
    Table 49. Asia Pacific Drugs for Oncology Market Size by Application (2023-2028) & (US$ Million)
    Table 50. Asia Pacific Drugs for Oncology Market Size by Region (2017-2022) & (US$ Million)
    Table 51. Asia Pacific Drugs for Oncology Market Size by Region (2023-2028) & (US$ Million)
    Table 52. Latin America Drugs for Oncology Market Size by Type (2017-2022) & (US$ Million)
    Table 53. Latin America Drugs for Oncology Market Size by Type (2023-2028) & (US$ Million)
    Table 54. Latin America Drugs for Oncology Market Size by Application (2017-2022) & (US$ Million)
    Table 55. Latin America Drugs for Oncology Market Size by Application (2023-2028) & (US$ Million)
    Table 56. Latin America Drugs for Oncology Market Size by Country (2017-2022) & (US$ Million)
    Table 57. Latin America Drugs for Oncology Market Size by Country (2023-2028) & (US$ Million)
    Table 58. Middle East and Africa Drugs for Oncology Market Size by Type (2017-2022) & (US$ Million)
    Table 59. Middle East and Africa Drugs for Oncology Market Size by Type (2023-2028) & (US$ Million)
    Table 60. Middle East and Africa Drugs for Oncology Market Size by Application (2017-2022) & (US$ Million)
    Table 61. Middle East and Africa Drugs for Oncology Market Size by Application (2023-2028) & (US$ Million)
    Table 62. Middle East and Africa Drugs for Oncology Market Size by Country (2017-2022) & (US$ Million)
    Table 63. Middle East and Africa Drugs for Oncology Market Size by Country (2023-2028) & (US$ Million)
    Table 64. Roche Company Details
    Table 65. Roche Business Overview
    Table 66. Roche Drugs for Oncology Product
    Table 67. Roche Revenue in Drugs for Oncology Business (2017-2022) & (US$ Million)
    Table 68. Roche Recent Developments
    Table 69. Celgene Company Details
    Table 70. Celgene Business Overview
    Table 71. Celgene Drugs for Oncology Product
    Table 72. Celgene Revenue in Drugs for Oncology Business (2017-2022) & (US$ Million)
    Table 73. Celgene Recent Developments
    Table 74. Novartis Company Details
    Table 75. Novartis Business Overview
    Table 76. Novartis Drugs for Oncology Product
    Table 77. Novartis Revenue in Drugs for Oncology Business (2017-2022) & (US$ Million)
    Table 78. Novartis Recent Developments
    Table 79. Bristol-Myers Squibb Company Details
    Table 80. Bristol-Myers Squibb Business Overview
    Table 81. Bristol-Myers Squibb Drugs for Oncology Product
    Table 82. Bristol-Myers Squibb Revenue in Drugs for Oncology Business (2017-2022) & (US$ Million)
    Table 83. Bristol-Myers Squibb Recent Developments
    Table 84. Johnson & Johnson Company Details
    Table 85. Johnson & Johnson Business Overview
    Table 86. Johnson & Johnson Drugs for Oncology Product
    Table 87. Johnson & Johnson Revenue in Drugs for Oncology Business (2017-2022) & (US$ Million)
    Table 88. Johnson & Johnson Recent Developments
    Table 89. Merck & Co. Company Details
    Table 90. Merck & Co. Business Overview
    Table 91. Merck & Co. Drugs for Oncology Product
    Table 92. Merck & Co. Revenue in Drugs for Oncology Business (2017-2022) & (US$ Million)
    Table 93. Merck & Co. Recent Developments
    Table 94. AstraZeneca Company Details
    Table 95. AstraZeneca Business Overview
    Table 96. AstraZeneca Drugs for Oncology Product
    Table 97. AstraZeneca Revenue in Drugs for Oncology Business (2017-2022) & (US$ Million)
    Table 98. AstraZeneca Recent Developments
    Table 99. Pfizer Company Details
    Table 100. Pfizer Business Overview
    Table 101. Pfizer Drugs for Oncology Product
    Table 102. Pfizer Revenue in Drugs for Oncology Business (2017-2022) & (US$ Million)
    Table 103. Pfizer Recent Developments
    Table 104. Amgen Company Details
    Table 105. Amgen Business Overview
    Table 106. Amgen Drugs for Oncology Product
    Table 107. Amgen Revenue in Drugs for Oncology Business (2017-2022) & (US$ Million)
    Table 108. Amgen Recent Developments
    Table 109. Eli Lilly Company Details
    Table 110. Eli Lilly Business Overview
    Table 111. Eli Lilly Drugs for Oncology Product
    Table 112. Eli Lilly Revenue in Drugs for Oncology Business (2017-2022) & (US$ Million)
    Table 113. Eli Lilly Recent Developments
    Table 114. AbbVie Company Details
    Table 115. AbbVie Business Overview
    Table 116. AbbVie Drugs for Oncology Product
    Table 117. AbbVie Revenue in Drugs for Oncology Business (2017-2022) & (US$ Million)
    Table 118. AbbVie Recent Developments
    Table 119. Takeda Company Details
    Table 120. Takeda Business Overview
    Table 121. Takeda Drugs for Oncology Product
    Table 122. Takeda Revenue in Drugs for Oncology Business (2017-2022) & (US$ Million)
    Table 123. Takeda Recent Developments
    Table 124. Astellas Company Details
    Table 125. Astellas Business Overview
    Table 126. Astellas Drugs for Oncology Product
    Table 127. Astellas Revenue in Drugs for Oncology Business (2017-2022) & (US$ Million)
    Table 128. Astellas Recent Developments
    Table 129. Ipsen Company Details
    Table 130. Ipsen Business Overview
    Table 131. Ipsen Drugs for Oncology Product
    Table 132. Ipsen Revenue in Drugs for Oncology Business (2017-2022) & (US$ Million)
    Table 133. Ipsen Recent Developments
    Table 134. Sanofi Company Details
    Table 135. Sanofi Business Overview
    Table 136. Sanofi Drugs for Oncology Product
    Table 137. Sanofi Revenue in Drugs for Oncology Business (2017-2022) & (US$ Million)
    Table 138. Sanofi Recent Developments
    Table 139. Bayer Company Details
    Table 140. Bayer Business Overview
    Table 141. Bayer Drugs for Oncology Product
    Table 142. Bayer Revenue in Drugs for Oncology Business (2017-2022) & (US$ Million)
    Table 143. Bayer Recent Developments
    Table 144. Biogen Idec Company Details
    Table 145. Biogen Idec Business Overview
    Table 146. Biogen Idec Drugs for Oncology Product
    Table 147. Biogen Idec Revenue in Drugs for Oncology Business (2017-2022) & (US$ Million)
    Table 148. Biogen Idec Recent Developments
    Table 149. Teva Company Details
    Table 150. Teva Business Overview
    Table 151. Teva Drugs for Oncology Product
    Table 152. Teva Revenue in Drugs for Oncology Business (2017-2022) & (US$ Million)
    Table 153. Teva Recent Developments
    Table 154. Otsuka Company Details
    Table 155. Otsuka Business Overview
    Table 156. Otsuka Drugs for Oncology Product
    Table 157. Otsuka Revenue in Drugs for Oncology Business (2017-2022) & (US$ Million)
    Table 158. Otsuka Recent Developments
    Table 159. Eisai Company Details
    Table 160. Eisai Business Overview
    Table 161. Eisai Drugs for Oncology Product
    Table 162. Eisai Revenue in Drugs for Oncology Business (2017-2022) & (US$ Million)
    Table 163. Eisai Recent Developments
    Table 164. Merck KGaA Company Details
    Table 165. Merck KGaA Business Overview
    Table 166. Merck KGaA Drugs for Oncology Product
    Table 167. Merck KGaA Revenue in Drugs for Oncology Business (2017-2022) & (US$ Million)
    Table 168. Merck KGaA Recent Developments
    Table 169. Gilead Sciences Company Details
    Table 170. Gilead Sciences Business Overview
    Table 171. Gilead Sciences Drugs for Oncology Product
    Table 172. Gilead Sciences Revenue in Drugs for Oncology Business (2017-2022) & (US$ Million)
    Table 173. Gilead Sciences Recent Developments
    Table 174. Research Programs/Design for This Report
    Table 175. Key Data Information from Secondary Sources
    Table 176. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Drugs for Oncology Market Share by Type: 2021 VS 2028
    Figure 2. Chemotherapy Features
    Figure 3. Targeted Therapy Features
    Figure 4. Immunotherapy (Biologic Therapy) Features
    Figure 5. Hormonal Therapy Features
    Figure 6. Others Features
    Figure 7. Global Drugs for Oncology Market Share by Application: 2021 VS 2028
    Figure 8. Blood Cancer Case Studies
    Figure 9. Breast Cancer Case Studies
    Figure 10. Gastrointestinal Cancer Case Studies
    Figure 11. Prostate Cancer Case Studies
    Figure 12. Respiratory/Lung Cancer Case Studies
    Figure 13. Others Case Studies
    Figure 14. Drugs for Oncology Report Years Considered
    Figure 15. Global Drugs for Oncology Market Size (US$ Million), Year-over-Year: 2017-2028
    Figure 16. Global Drugs for Oncology Market Size, (US$ Million), 2017 VS 2021 VS 2028
    Figure 17. Global Drugs for Oncology Market Share by Region: 2021 VS 2028
    Figure 18. Global Drugs for Oncology Market Share by Players in 2021
    Figure 19. Global Top Drugs for Oncology Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Oncology as of 2021)
    Figure 20. The Top 10 and 5 Players Market Share by Drugs for Oncology Revenue in 2021
    Figure 21. North America Drugs for Oncology Market Size YoY (2017-2028) & (US$ Million)
    Figure 22. North America Drugs for Oncology Market Size Market Share by Type (2017-2028)
    Figure 23. North America Drugs for Oncology Market Size Market Share by Application (2017-2028)
    Figure 24. North America Drugs for Oncology Market Size Share by Country (2017-2028)
    Figure 25. United States Drugs for Oncology Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 26. Canada Drugs for Oncology Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 27. Europe Drugs for Oncology Market Size YoY (2017-2028) & (US$ Million)
    Figure 28. Europe Drugs for Oncology Market Size Market Share by Type (2017-2028)
    Figure 29. Europe Drugs for Oncology Market Size Market Share by Application (2017-2028)
    Figure 30. Europe Drugs for Oncology Market Size Share by Country (2017-2028)
    Figure 31. Germany Drugs for Oncology Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 32. France Drugs for Oncology Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 33. U.K. Drugs for Oncology Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 34. Italy Drugs for Oncology Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 35. Russia Drugs for Oncology Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 36. Nordic Countries Drugs for Oncology Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 37. Asia-Pacific Drugs for Oncology Market Size YoY (2017-2028) & (US$ Million)
    Figure 38. Asia Pacific Drugs for Oncology Market Size Market Share by Type (2017-2028)
    Figure 39. Asia Pacific Drugs for Oncology Market Size Market Share by Application (2017-2028)
    Figure 40. Asia Pacific Drugs for Oncology Market Size Share by Region (2017-2028)
    Figure 41. China Drugs for Oncology Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 42. Japan Drugs for Oncology Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 43. South Korea Drugs for Oncology Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 44. Southeast Asia Drugs for Oncology Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 45. India Drugs for Oncology Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 46. Australia Drugs for Oncology Market Size YoY Growth (2017-2028) & (US$ Million)
List of Figures
    Figure 47. Latin America Drugs for Oncology Market Size YoY (2017-2028) & (US$ Million)
    Figure 48. Latin America Drugs for Oncology Market Size Market Share by Type (2017-2028)
    Figure 49. Latin America Drugs for Oncology Market Size Market Share by Application (2017-2028)
    Figure 50. Latin America Drugs for Oncology Market Size Share by Country (2017-2028)
    Figure 51. Mexico Drugs for Oncology Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 52. Brazil Drugs for Oncology Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 53. Middle East & Africa Drugs for Oncology Market Size YoY (2017-2028) & (US$ Million)
    Figure 54. Middle East and Africa Drugs for Oncology Market Size Market Share by Type (2017-2028)
    Figure 55. Middle East and Africa Drugs for Oncology Market Size Market Share by Application (2017-2028)
    Figure 56. Middle East and Africa Drugs for Oncology Market Size Share by Country (2017-2028)
    Figure 57. Turkey Drugs for Oncology Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 58. Saudi Arabia Drugs for Oncology Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 59. UAE Drugs for Oncology Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 60. Roche Revenue Growth Rate in Drugs for Oncology Business (2017-2022)
    Figure 61. Celgene Revenue Growth Rate in Drugs for Oncology Business (2017-2022)
    Figure 62. Novartis Revenue Growth Rate in Drugs for Oncology Business (2017-2022)
    Figure 63. Bristol-Myers Squibb Revenue Growth Rate in Drugs for Oncology Business (2017-2022)
    Figure 64. Johnson & Johnson Revenue Growth Rate in Drugs for Oncology Business (2017-2022)
    Figure 65. Merck & Co. Revenue Growth Rate in Drugs for Oncology Business (2017-2022)
    Figure 66. AstraZeneca Revenue Growth Rate in Drugs for Oncology Business (2017-2022)
    Figure 67. Pfizer Revenue Growth Rate in Drugs for Oncology Business (2017-2022)
    Figure 68. Amgen Revenue Growth Rate in Drugs for Oncology Business (2017-2022)
    Figure 69. Eli Lilly Revenue Growth Rate in Drugs for Oncology Business (2017-2022)
    Figure 70. AbbVie Revenue Growth Rate in Drugs for Oncology Business (2017-2022)
    Figure 71. Takeda Revenue Growth Rate in Drugs for Oncology Business (2017-2022)
    Figure 72. Astellas Revenue Growth Rate in Drugs for Oncology Business (2017-2022)
    Figure 73. Ipsen Revenue Growth Rate in Drugs for Oncology Business (2017-2022)
    Figure 74. Sanofi Revenue Growth Rate in Drugs for Oncology Business (2017-2022)
    Figure 75. Bayer Revenue Growth Rate in Drugs for Oncology Business (2017-2022)
    Figure 76. Biogen Idec Revenue Growth Rate in Drugs for Oncology Business (2017-2022)
    Figure 77. Teva Revenue Growth Rate in Drugs for Oncology Business (2017-2022)
    Figure 78. Otsuka Revenue Growth Rate in Drugs for Oncology Business (2017-2022)
    Figure 79. Eisai Revenue Growth Rate in Drugs for Oncology Business (2017-2022)
    Figure 80. Merck KGaA Revenue Growth Rate in Drugs for Oncology Business (2017-2022)
    Figure 81. Gilead Sciences Revenue Growth Rate in Drugs for Oncology Business (2017-2022)
    Figure 82. Bottom-up and Top-down Approaches for This Report
    Figure 83. Data Triangulation
    Figure 84. Key Executives Interviewed